Clinical Trials Browser

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

Breast

HER2-positive Early Breast Cancer

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast

Breast Neoplasms

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Phase 3 Completed

446 enrolled

Breast

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

226 enrolled

Breast

Breast Neoplasms

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Phase 3 Completed

355 enrolled

Breast

HER2-positive Breast Cancer

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Phase 3 Completed

1,486 enrolled 37 charts 1 FDA

Breast

Breast Neoplasms

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Phase 3 Completed

3,270 enrolled 16 charts

Breast

Breast Neoplasms

NCT00769379 2025-06-12

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Phase 3 Completed

2,014 enrolled 16 charts

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01526369 2025-05-09

TH V THL

Phase 3 Completed

75 enrolled

Breast

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

Phase 3 Completed

8,381 enrolled 22 charts

Breast

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Phase 3 Completed

652 enrolled 50 charts

Breast

Breast Neoplasms

NCT02492711 2025-03-17

SOPHIA

Phase 3 Completed

624 enrolled 17 charts 2 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3 Completed

369 enrolled 19 charts

Breast

Breast Neoplasms

NCT01084876 2025-02-11

Compare

Phase 3 Completed

475 enrolled 25 charts

Breast

Breast Neoplasms

NCT02578368 2024-11-12

FLOT5

Phase 3 Completed

183 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03013504 2024-11-06

TROIKA

Phase 3 Completed

503 enrolled

Breast

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast

Breast Neoplasms

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Phase 3 Completed

108 enrolled 7 charts

Breast

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 2 FDA

Breast

Breast Neoplasms

NCT03084237 2024-05-17

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

Phase 3 Completed

652 enrolled 15 charts

Breast

Breast Neoplasms

NCT05629949 2024-04-23

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Phase 3 Completed

474 enrolled

Breast

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3 Completed

1,095 enrolled 46 charts

Breast

Breast Neoplasms

NCT03989037 2023-12-27

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Phase 3 Completed

580 enrolled

Breast

HER2-positive Early Breast Cancer

NCT06107790 2023-10-30

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Phase 3 Completed

570 enrolled

Breast

HER2-positive Breast Cancer

NCT02586025 2023-05-22

PEONY

Phase 3 Completed

329 enrolled 33 charts

Breast

Breast Neoplasms

NCT01875367 2023-04-05

ChangHER-SC

Phase 3 Completed

166 enrolled 24 charts

Breast

Breast Neoplasms

NCT03433313 2023-01-20

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Phase 3 Completed

807 enrolled

Breast

Breast Neoplasms

NCT03705429 2022-08-19

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Phase 3 Completed

51 enrolled

Breast

Breast Neoplasms

NCT02162667 2022-08-03

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Phase 3 Completed

562 enrolled 15 charts

Breast

HER2-positive Carcinoma of Breast

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Phase 3 Completed

809 enrolled 14 charts

Breast

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

Phase 3 Completed

243 enrolled 23 charts

Breast

Breast Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

Phase 3 Completed

455 enrolled 34 charts

Breast

Breast Neoplasms, Osteitis Deformans

NCT01989676 2021-07-06

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Phase 3 Completed

707 enrolled 20 charts

Breast

Breast Neoplasms

NCT00004067 2021-04-29

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Phase 3 Completed

2,130 enrolled

Breast

Breast Neoplasms

NCT01566721 2021-04-27

SafeHER

Phase 3 Completed

2,577 enrolled 16 charts 1 FDA

Breast

Breast Neoplasms

NCT01940497 2020-11-03

SCHEARLY

Phase 3 Completed

240 enrolled 14 charts

Breast

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

Phase 3 Completed

1,436 enrolled 53 charts

Breast

Breast Neoplasms

NCT01810393 2020-09-04

A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Phase 3 Completed

114 enrolled

Breast

Breast Neoplasms

NCT00005970 2020-08-14

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3 Completed

3,436 enrolled

Breast

Breast Neoplasms

NCT00047255 2020-08-03

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Phase 3 Completed

263 enrolled

Breast

Breast Neoplasms

NCT01950182 2020-07-15

SYSUCC-002

Phase 3 Completed

392 enrolled

Breast

Breast Neoplasms

NCT01104935 2019-10-21

RESPECT

Phase 3 Completed

275 enrolled

Breast

Breast Neoplasms

NCT01926886 2019-09-18

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

Phase 3 Completed

102 enrolled 8 charts

Breast

Breast Neoplasms

NCT02402712 2019-09-06

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Phase 3 Completed

418 enrolled

Breast

Breast Neoplasms

NCT02040935 2019-08-22

HOMERUS

Phase 3 Completed

128 enrolled

Breast

Breast Neoplasms